Clinical trials: Metastatic Renal Cancer
Advanced Solid Tumors
Phase 1 Study of OSI-930 in Cancer Patients
Open label, phase 1, dose escalation
- Trial name
- NCT00513851
- Testing
- OSI-930
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Renal Cell Carcinoma
A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
This is an open-label, single arm , Ib/II phase trial to evaluate the efficacy and safety of AK112（ivonescimab）monotherapy as first-line treatment for favourable risk advanced/metastatic renal cell carcinoma (a/m RCC).
- Trial name
- NCT06472895
- Testing
- AK112 monotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Kidney Cancer
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00747305
- Testing
- sunitinib malate, gene expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Harry Drabkin
Metastatic Renal Cell Carcinoma, Brain Metastases
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has…
- Trial name
- NCT06132945
- Testing
- Cabozantinib, Nivolumab, Stereotactic Radiosurgery (SRS)
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy
The purpose of this study is to estimate overall survival over a 5-year follow-up period among adult participants with advanced/metastatic kidney cancer, starting 1st line nivolumab and ipilimumab combination therapy or nivolumab…
- Trial name
- NCT02940639
- Where
- Germany
- Volunteers
- 499 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug that are known to target specific cells (in this case, cells in the immune system) The DC RCC Vaccine is agent that tries to help the…
- Trial name
- NCT01441765
- Testing
- CT-011, DC/RCC fusion vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Beth Israel Deaconess Medical Center
Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
This Single-arm, multicentre, phase 2 trial aims determine the activity and safety of pembrolizumab and denosumab in advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- KEYPAD (NCT03280667)
- Testing
- Pembrolizumab plus denosumab
- Where
- 16 sites in Australia
- Volunteers
- 59 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Renal Cell Carcinoma
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
Reported in the 2018 NEJM (378; 1277) article, the combination of checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody) phase III trial Checkmate 214 demonstrated statistically significant…
- Trial name
- PIVOT-RCC (NCT03598816)
- Testing
- Durvalumab, Tremelimumab, TDS-IM v1.0 System
- Sponsor
- Washington University School of Medicine
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00006111
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 11 sites in France
- Volunteers
- 53 people
- Sponsor
- UNICANCER
Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.
- Conditions
- Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma
- Trial name
- NCT03635892
- Testing
- cabozantinib, nivolumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
This pilot clinical trial studies stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery.
- Trial name
- NCT01892930
- Testing
- stereotactic body radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
This phase I/II trial studies the side effects and best dose of entinostat when given together with aldesleukin and to see how well this works in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01038778
- Testing
- Aldesleukin, Computed Tomography, Entinostat
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Cancer, Breast
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people.
- Conditions
- Metastatic Cancer, Cancer, Breast, Cancer Colon, Cancer, Rectum
- Trial name
- SPACE2 (NCT05154474)
- Testing
- Standard
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Weprom
Kidney Cancer, Liver Cancer
Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)
The study includes the recruitment of patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with sorafenib. Multicenter cohort study. It is a prospective observational study.
- Trial name
- SORHORM (NCT01230697)
- Testing
- Sorafenib
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Turin, Italy
Metastatic Renal Cell Carcinoma
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
- Trial name
- CYTOSHRINK (NCT04090710)
- Testing
- Ipilimumab/ Nivolumab, SBRT + Ipilimumab/Nivolumab
- Where
- 7 sites in Australia, Canada
- Volunteers
- 66 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Metastatic Renal Cell Carcinoma
TIL Therapy for Metastatic Renal Cell Carcinoma
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma.
- Trial name
- NCT02926053
- Testing
- Surgical removal of tumor tissue for T cell production, Cyclophosphamide, Fludarabine
- Where
- Denmark
- Volunteers
- 5 people
- Sponsor
- Inge Marie Svane
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Carcinoma, Renal Cell, Kidney Diseases
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.
- Conditions
- Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02386111
- Testing
- Combination of varlilumab and sunitinib
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Celldex Therapeutics
Distal Urethral Cancer, Proximal Urethral Cancer
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer.
- Conditions
- Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00471536
- Testing
- pazopanib hydrochloride
- Where
- 9 sites in United States, China and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.